[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Avalo Therapeutics Inc (AVTX)

Avalo Therapeutics Inc (AVTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Market News and Commentary

Avalo Therapeutics Reports First Results Since LOTUS Trial Success Changed Everything—Or Did It

Avalo Therapeutics (AVTX) is scheduled to report first-quarter 2026 earnings on May 11, 2026, with the stock trading at $21.57 ahead of the release. The central question for investors is whether the company can sustain the dramatic improvement seen in its most recent quarter—when it delivered a stunning 76% earnings beat—or if that result was an anomaly amid a broader pattern of significant misses. With the stock up 164% over the past year and analysts overwhelmingly bullish, this report will test whether AVTX's clinical progress can translate into sustained financial performance.

Avalo Therapeutics is a clinical-stage biotechnology company focused on developing novel therapies for...

Fundamentals

See More
  • Market Capitalization, $K 576,221
  • Shares Outstanding, K 26,714
  • Annual Sales, $ 60 K
  • Annual Income, $ -78,260 K
  • EBIT $ -73 M
  • EBITDA $ -73 M
  • 60-Month Beta 0.78
  • Price/Sales 10,355.07
  • Price/Cash Flow N/A
  • Price/Book 5.10

Options Overview Details

View History
  • Implied Volatility 87.47% (-0.67%)
  • Historical Volatility 124.30%
  • IV Percentile 2%
  • IV Rank 8.59%
  • IV High 506.06% on 05/04/26
  • IV Low 48.13% on 09/04/25
  • Expected Move (DTE 6) 2.10 (9.73%)
  • Put/Call Vol Ratio 3.38
  • Today's Volume 1,428
  • Volume Avg (30-Day) 4,201
  • Put/Call OI Ratio 0.97
  • Today's Open Interest 106,904
  • Open Int (30-Day) 82,843
  • Expected Range 19.47 to 23.67

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 14 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-1.00
  • Number of Estimates 4
  • High Estimate $-0.85
  • Low Estimate $-1.10
  • Prior Year $-1.25
  • Growth Rate Est. (year over year) +20.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
12.51 +72.42%
on 04/29/26
24.27 -11.12%
on 05/07/26
+7.16 (+49.69%)
since 04/08/26
3-Month
12.51 +72.42%
on 04/29/26
24.27 -11.12%
on 05/07/26
+7.38 (+52.01%)
since 02/06/26
52-Week
3.39 +536.28%
on 05/14/25
24.27 -11.12%
on 05/07/26
+17.22 (+395.86%)
since 05/08/25

Most Recent Stories

More News
Avalo Therapeutics Reports First Results Since LOTUS Trial Success Changed Everything—Or Did It

Barchart Research What to Expect from AVTX Earnings AVTX Generated May 8, 2026 Current Price $21.57 EPS Estimate $$-1.00 Consensus Rating Strong Buy Average Move 3.29% Avalo Therapeutics Reports First...

AVTX : 21.57 (-5.68%)
Avalo Therapeutics Announces Pricing of $375 Million Public Offering

WAYNE, Pa., May 05, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ: AVTX) (“Avalo”), a clinical-stage biotechnology company fully dedicated to developing IL-1β based treatments for immune-mediated...

AVTX : 21.57 (-5.68%)
Avalo Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

WAYNE, Pa., May 05, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ: AVTX) (“Avalo”), a clinical-stage biotechnology company fully dedicated to developing IL-1β based treatments for immune-mediated...

AVTX : 21.57 (-5.68%)
Avalo Therapeutics Achieves Positive Topline Results in Phase 2 LOTUS Trial of Abdakibart (AVTX-009) in Moderate to Severe Hidradenitis Suppurativa

Successfully met primary endpoint of HiSCR75 for both doses studied, demonstrating response rates of 42.2% for 150 mg dose (p=0.018) and 42.9% for 300 mg dose (p=0.015) at Week 16, which are the highest...

AVTX : 21.57 (-5.68%)
Avalo Therapeutics Purchases Optional Milestone Buyout

WAYNE, Pa., April 28, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) (“Avalo”), a clinical-stage biotechnology company fully dedicated to developing IL-1β based treatments for...

AVTX : 21.57 (-5.68%)
Avalo Therapeutics Reports 2025 Financial Results and Recent Business Updates

Topline data expected from Phase 2 LOTUS trial of abdakibart (AVTX-009) for the treatment of hidradenitis suppurativa in the second quarter of 2026 Cash, cash equivalents and short-term investments...

AVTX : 21.57 (-5.68%)
Avalo Therapeutics to Participate in Upcoming Investor Conferences

WAYNE, Pa., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated...

AVTX : 21.57 (-5.68%)
Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

WAYNE, Pa., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated...

AVTX : 21.57 (-5.68%)
Avalo Therapeutics to Participate in Upcoming Investor Conferences

WAYNE, Pa., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated...

AVTX : 21.57 (-5.68%)
Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

WAYNE, Pa., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated...

AVTX : 21.57 (-5.68%)

Business Summary

Avalo Therapeutics Inc. is a clinical-stage precision medicine company which discovers, develops and commercializes targeted therapeutics for patients with significant unmet clinical need in immunology, immuno-oncology and rare genetic diseases. Avalo Therapeutics Inc., formerly known as Cerecor, is...

See More

Key Turning Points

3rd Resistance Point 24.69
2nd Resistance Point 23.83
1st Resistance Point 22.70
Last Price 21.57
1st Support Level 20.71
2nd Support Level 19.85
3rd Support Level 18.72

See More

52-Week High 24.27
Last Price 21.57
Fibonacci 61.8% 16.29
Fibonacci 50% 13.83
Fibonacci 38.2% 11.37
52-Week Low 3.39

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.